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Abstract
Background: Troponins (highly sensitive biomarkers of myocardial damage) increase counts of myocardial
infarction (MI) in clinical practice, but their impact on trends in admission rates for MI in National statistics is
uncertain.
Methods: Cases coded as MI or other cardiac diagnoses in the Hospital Morbidity Data Collection (MI-HMDC) in
Western Australia in 1998 and 2003 were classified using revised criteria for MI developed by an International panel
convened by the American Heart Association (AHA criteria) using information on symptoms, ECGs and cardiac
biomarkers abstracted from samples of medical notes. Age-sex standardized rates of MI-HMDC were compared
with rates of MI based on AHA criteria including troponins (MI-AHA) or traditional biomarkers only (MI-AHAck).
Results: Between 1998 and 2003, rates of MI-HMDC decreased by 3.5% whereas rates of MI-AHA increased by 17%,
a difference largely due to increased false-negative cases in the HMDC associated with marked increased use of
troponin tests in cardiac admissions generally, and progressively lower test thresholds. In contrast, rates of MI-
AHAck declined by 18%.
Conclusions: Increasing misclassification of MI-AHA by the HMDC may be due to reluctance by clinicians to
diagnose MI based on relatively small increases in troponin levels. These influences are likely to continue.
Monitoring MI using AHA criteria will require calibration of commercially available troponin tests and agreement on
lower diagnostic thresholds for epidemiological studies. Declining rates of MI-AHAck are consistent with long-
standing trends in MI in Western Australia, suggesting that neither MI-HMDC nor MI-AHA reflect the true
underlying population trends in MI.
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Background
Coronary heart disease (CHD), despite declining mortality,
remains a major health problem in developed countries
[1-3]. Reliable methods for monitoring acute CHD events,
including myocardial infarction (MI), are therefore essen-
tial for evaluation of preventive and clinical services, parti-
cularly in view of the increasing prevalence of obesity and
diabetes that could diminish or reverse the favourable
trends in mortality. The World Health Organization
(WHO) MONICA Project, which monitored trends and
determinants of coronary heart disease including non-fatal
MI for 10 years in 25 countries between 1983 and 1995,
demonstrated the importance of population-based regis-
ters to monitor MI, using standardised methods of case-
finding and unchanging diagnostic criteria. Unfortunately,
such registers are costly and there have been few recent
national or international register-based studies of trends in
MI [4-7].
In many jurisdictions, routinely collected mortality and
hospital morbidity data are therefore the most commonly
used alternative for monitoring trends in MI. While such
data have major shortcomings, studies in Finland, Sweden
and Western Australia have previously shown reasonable
agreement between trends based on registers and adminis-
trative data [7-9]. However, the recent widespread
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specific biomarkers of myocardial damage, particularly tro-
ponin tests, raises doubts about the reliability of adminis-
trative data for monitoring MI. Several studies have
demonstrated greatly increased counts of MI using tropo-
nin tests compared with traditional biomarkers [4,10].
Studies in Perth, Western Australia, and Denmark have
shown that declining trends in hospital MI admissions
reversed or levelled out since the introduction of troponin
tests in 1996 [5,11].
In recognition of the potential problems for epidemiolo-
gical studies, a panel of international experts, meeting
under the auspices of the American Heart Association
(AHA), have developed new criteria for MI for use in epi-
demiological studies, referred to here as the ‘AHA criteria’,
which emphasise the importance of troponin in the diag-
nosis of MI [12]. So far, there have been few population-
based studies exploring the practical issues of implement-
ing the new criteria or assessing the impact of troponin
tests on trends in MI based on administrative data.
This study used the Hospital Morbidity Data Collec-
tion (HMDC), one of the core administrative datasets in
the Western Australian Data Linkage System [13], to
compare counts of non-fatal MI (MI-HMDC) in 1998
and 2003 with counts based on AHA criteria using all
biomarkers including troponins (MI-AHA), or tradi-
tional biomarkers only (MI-AHAck) including creatinine
kinase (CK) or CK-MB in the classification algorithm.
Methods
The study population consisted of residents of the Perth
Statistical Division (population 1.43 million in 2003) of
Western Australia aged 35-79 years admitted to hospital
in 1998 or 2003 for cardiac conditions or chest pain
(International Classification of Diseases (ICD) 9
th revi-
sion codes 401-429, 786.5; or ICD10 Australian Modifi-
cation codes I10-I52, R07). Electronic records for the
study population were extracted from the HMDC, iden-
tified by hierarchical discharge diagnosis as shown in
Table 1, then linked to provide 28-day episodes of care.
Non-fatal cases were defined as patients who were
alive 28 days after admission. The episode records were
then linked electronically to results of cardiac biomar-
kers provided by biochemistry departments. Cases were
then selected for validation of discharge diagnosis codes
against information abstracted from medical notes,
using the sampling scheme outlined in Additional File 1,
Table S1. In brief, cases for validation consisted of ran-
dom samples of all non-fatal cases coded as MI or
unstable angina pectoris (UAP) in any diagnosis field, or
cases with a principal diagnosis of other heart disease or
chest pain who had positive biomarker test results (sus-
pected false negative MI). We excluded booked admis-
sions for coronary artery bypass surgery or heart valve
operations; angiograms with length of stay ≤ 1d a y ;a n d
heart transplants.
Data were abstracted from medical notes directly into
a Microsoft Access database by trained staff using a
standardised data collection format. Data included:
symptoms present on admission, results of biomarker
tests (daily results for up to 5 days), reasons for possible
false elevations of cardiac biomarkers (such as angio-
plasty, cardiac surgery, other major surgery, trauma,
severe renal failure), and photocopies of up to five elec-
trocardiographs (ECG). Other data, including demo-
graphic details and dates, were added directly from the
HMDC extract.
Classification of myocardial infarction by ‘AHA criteria’
A computer algorithm was developed to classify cases as
Definite, Probable, Possible or Not MI according to
AHA criteria based on the combination of symptoms,
biomarker results and ECG abnormalities as defined in
the International panel report [12] and illustrated in
Additional File 1, Table S2.
Statistical analyses
All analyses were carried out in SAS version 9.1.3 SP4
for Windows. Population estimates of the total number
of cases in each sample group were calculated by inflat-
ing the sampled cases by their sampling fraction (see
Additional File 1, Table S1). This was achieved using
the inverse of the sampling fraction as the variable in
the weight statement of Proc Freq in SAS, and in Proc
SurveyFreq when calculating sensitivity and PPV. Results
are reported as counts and proportions, together with
population estimates of sensitivity, positive predictive
value (PPV) and their 95% confidence intervals for the
HMDC coding of MI relative to ‘AHA criteria’ for Defi-
nite/Probable MI (Positive MI) and Definite/Probable/
Possible MI (Any MI). The percentage by which HMDC
misclassified MI as defined by ‘AHA criteria’ was calcu-
lated by

sensitivity
PPV
− 1

× 100%.
Counts of MI-HMDC were compared separately with
counts of MI based on AHA criteria using all available
biomarkers, including troponins (MI-AHA), or tradi-
tional biomarkers only (MI-AHAck). To allow for the
effect of population increase between 1998 and 2003, we
estimated age-sex standardised rates of admission for
non-fatal MI in age group 35-79 years using the direct
method by 5-year age group and sex, with the Australian
estimated population at 30 June 2001 as the standard.
Diagnostic thresholds for troponin tests were lower in
2003 than in 1998 as the sensitivity of the assays
improved. We compared the distribution of ECG
changes and biomarker results in cases of Positive MI
coded in the HMDC as MI (true-positives) or Not MI
Sanfilippo et al. BMC Cardiovascular Disorders 2011, 11:35
http://www.biomedcentral.com/1471-2261/11/35
Page 2 of 8(false-negatives) to examine the extent to which the
lower thresholds were associated with false-negative
cases.
Ethics approval
This study was approved by the Human Research Ethics
Committees of the University of Western Australia,
each of the eight hospitals from which data were col-
lected, and by the Western Australian Confidentiality of
Health Information Committee. The study was granted
a waiver of informed consent.
Results
In 1998, there were 8939 28-day episodes of care for heart
conditions or chest pain (Table 1) of which 3522 met our
criteria for validation (see Additional File 1, Table S1) and
from which 1456 non-fatal episodes were sampled for vali-
dation against medical notes. The equivalent numbers for
2003 were 9188 episodes of care, 3297 meeting validation
criteria and 1108 sampled for validation. Between 1998
and 2003, episodes of care for MI increased by 11% whilst
those for UAP decreased by 26%. In 1998, 81% of episodes
of care for MI and 53% of UAP had troponin tests,
increasing to 97% and 93% respectively in 2003. In com-
parison, the traditional biomarkers (CK and CK-MB) were
used in 96% of episodes of MI care in 1998 and 93% in
2003. The prevalence of troponin tests in cases not coded
as MI or UAP increased from 33% to 63%.
AHA classification scheme
Full details of the final AHA diagnostic classification of
validated cases together with corresponding classifications
of symptoms, ECG and biomarker results for 1998 and
2003 are shown in Additional File 1, Table S2. A feature
of this is the dominating influence of biomarkers, particu-
larly troponins, on the classification of MI. For example, in
1998, 74.8% of cases were classified as Definite MI because
of biomarkers alone, whilst only 6.8% were classified as
Definite MI based on evolving ECG changes alone. The
corresponding values in 2003 were 81.1% (1342/1654) and
8.3% (138/1654).
Comparison of MI-HMDC and MI-AHA
Table 2 shows the AHA classification of MI cross-tabu-
lated by HMDC diagnosis. As there were few cases of
AHA Probable MI in either year (1.2% in 1998 and 3.5%
in 2003), these were combined with Definite MI in all
tables (Positive MI). The sensitivity, positive predictive
value (PPV) and estimated misclassification of MI-
HMDC for Positive MI and Any MI are shown in Table
3. In 1998, MI-HMDC overestimated Positive MI by
7.4% but underestimated this by 10.7% in 2003. Any MI
(Positive + Possible MI) was underestimated by 12.4% in
1998 and by 21.3% in 2003. These temporal changes in
misclassification between 1998 and 2003 resulted from
general improvement in PPV (from 77.3% to 83.5% for
Positive MI) but deteriorating sensitivity (from 82.9% to
74.6%). For example, in 1998, 12.3% of cases classified
as Positive MI were coded as UAP in the HMDC (Table
2), and 4.8% as other heart diseases or chest pain, but in
2003 the respective proportions were 15.1% for UAP
and 10.3% for other cardiac conditions. When condi-
tions other than ischemic heart disease were excluded
from the analysis, the sensitivity of MI-HMDC increased
Table 1 Hierarchical classification of cardiovascular discharge diagnoses in non-fatal cases which identified the
validation population and sample
Diagnosis ICD codes 1998 2003
ICD-9-CM ICD-10-AM Counts
(n = 8939)
% Troponin tests
a Counts
(n = 9188)
% Troponin tests
a
MI
b 410 I21, I22 1425 81 1582 97
Unstable angina
b 411.1 I20.0 2024 53 1507 93
Other IHD
c
Other Angina other 411, 413 other I20 620 37 548 75
Other IHD rest of 410-414 I24, I25 135 15 216 54
Other CVD
c
Heart Failure 428 I50 820 32 655 79
Valve Disorders 424.0, 424.1 I34, I35 59 19 66 29
Arrhythmia 427 I46-I49 1557 21 1723 46
Hypertension 401-405 I10-I15 159 4 100 30
Other cardiovascular rest of 401-429 rest of I10-I52 515 20 514 51
Chest pain
c 786.5 R07 1625 46 2277 82
Cases were based on 28-day episodes of care. CVD: cardiovascular disease; ICD: International Classification of Diseases; IHD: ischaemic heart disease.
a % troponin tests = proportion of cases who had at least one troponin test.
b From any diagnosis field of the HMDC (Hospital Morbidity Data Collection).
c From principal diagnosis field of the HMDC.
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in 2003.
Table 3 also demonstrates some variation in PPV and
sensitivity of MI-HMDC by broad age group and sex,
but there was no consistent pattern except for generally
lower PPV and sensitivity in the 70-79 year age group,
and the variation could be due to chance as seen
through the 95% confidence intervals.
Characteristics of false-negative cases
To understand the declining sensitivity of MI-HMDC
between 1998 and 2003 we studied the distributions of
ECG changes and biomarker results in false-negative
cases (AHA Positive MI, but not coded as MI in the
HMDC). In 1998, 49% of MI-HMDC had ECG evi-
dence of MI (diagnostic or positive ECGs), compared
with 31% in false-negative cases. In 2003, the corre-
sponding percentages were 42% and 23%. Conversely,
in both years 28% of MI-HMDC had normal/other
ECGs compared with around 45% in false-negative
cases. We also found that troponin levels were sub-
stantially lower in false-negative cases than in true-
positive cases as illustrated in Figure 1 which compares
the distribution of troponin levels in true-positive and
Table 2 Hierarchical diagnosis and classification of myocardial infarction based on AHA Criteria for non-fatal
population estimates
Year HMDC episodes of care AHA classification of MI
a n (row%, col%)
Hierarchical diagnosis Count Positive MI Any MI Not MI
1998 MI 1420 1098 (77.3, 82.9) 1309 (92.2, 80.8) 111 (7.8, 5.8)
Unstable angina 2011 163 (8.1, 12.3) 233 (11.6, 14.4) 1778 (88.4, 93.5)
Other IHD
b 22 14 (63.6, 1.1) 20 (90.9, 1.2) 2 (9.1, 0.1)
Other CVD
b 69 49 (71.0, 3.7) 58 (84.1, 3.6) 11 (15.9, 0.6)
Total 3522 1324 1620
c 1902
2003 MI 1579 1318 (83.5, 74.6) 1479 (93.7, 73.8) 100 (6.3, 7.7)
Unstable angina 1493 267 (17.9, 15.1) 329 (22.0, 16.4) 1164 (78.0, 90.1)
Other IHD
b 48 46 (95.8, 2.6) 46 (95.8, 2.3) 2 (4.2, 0.2)
Other CVD
b 177 137 (77.4, 7.7) 151 (85.3, 7.5) 26 (14.7, 2.0)
Total 3297 1768 2005
c 1292
AHA: American Heart Association; CVD: cardiovascular disease; IHD: ischaemic heart disease; MI: myocardial infarction; Positive MI: AHA Definite or Probable MI;
Any MI: AHA Definite/Probable/Possible MI.
a Luepker et al [12]. Row% represents positive predictive value, col% represents sensitivity.
b As listed in Table 1 (Other CVD includes chest pain).
c Includes 66 cases (1998) and 64 cases (2003) downgraded from Definite due to absence of diagnostic troponin test.
Table 3 Sensitivity and PPV of MI-HMDC for non-fatal population estimates based on AHA classification of myocardial
infarction
Group 1998 2003
Sn, 95% CI PPV, 95% CI Sn/PPV
a Sn, 95% CI PPV, 95% CI Sn/PPV
a
Positive MI
b
Total non-fatal 82.9 80.3, 85.6 77.3 74.2, 80.4 1.07 (+7.4) 74.6 72.9, 76.2 83.5 79.4, 87.6 0.89 (-10.7)
All males 83.2 80.2, 86.3 76.6 72.9, 80.3 1.09 (+8.6) 76.5 74.6, 78.3 85.6 81.0, 90.2 0.89 (-10.6)
All females 82.2 77.0, 87.3 79.1 73.4, 84.8 1.04 (+3.9) 69.6 65.7, 73.4 77.9 69.1, 86.8 0.89 (-10.7)
All 35-69 years 83.8 80.3, 87.4 81.6 78.0, 85.2 1.03 (+2.7) 77.4 75.3, 79.6 85.0 80.1, 89.9 0.91 (-8.9)
All 70-79 years 81.2 77.2, 85.3 70.0 64.4, 75.6 1.16 (+16.0) 69.9 67.0, 72.8 80.6 73.0, 88.1 0.87 (-13.3)
Any MI
b
Total non-fatal 80.8 78.5, 83.1 92.2 90.2, 94.2 0.88 (-12.4) 73.8 72.2, 75.2 93.7 90.9, 96.4 0.79 (-21.3)
All males 80.5 77.9, 83.2 92.1 89.7, 94.4 0.87 (-12.6) 76.2 74.6, 77.7 94.3 (91.3, 97.3 0.81 (-19.2)
All females 81.6 76.9, 86.2 92.5 88.9, 96.2 0.88 (-11.8) 67.7 64.2, 71.2 91.9 86.0, 97.7 0.74 (-26.3)
All 35-69 years 80.7 77.5, 83.9 94.2 92.0, 96.4 0.86 (-14.3) 76.9 75.0, 78.8 94.7 91.6, 97.8 0.81 (-18.8)
All 70-79 years 80.8 77.6, 84.1 88.7 84.8, 92.6 0.91 (-8.9) 68.9 66.4, 71.3 91.7 86.4, 96.9 0.75 (-24.9)
95% CI: 95% confidence interval; AHA: American Heart Association; HMDC: Hospital Morbidity Data Collection; MI: myocardial infarction; MI-HMDC: MI coded in
the HMDC; Positive MI: AHA Definite or Probable MI; Any MI: AHA Definite/Probable/Possible MI; PPV: positive predictive value; Sn: sensitivity.
a Ratio of sensitivity to PPV: number in parentheses represents the percentage by which the HMDC over-estimates (+) or under-estimates (-) the number of cases
of MI in the population as defined by the ‘AHA criteria’.
b Luepker et al [12].
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2003.
Comparison of counts of MI based on troponins or
traditional biomarkers
Table 4 shows the AHA classification by HMDC diag-
nosis when troponin tests are excluded from the classifi-
cation algorithm. Compared with Table 2, this shows
that troponin tests increased the number of Positive MI
cases from 913 to 1324 in 1998 (45% increase) and from
853 to 1768 in 2003 (107% increase). For Any MI, tro-
ponin tests were associated with 43% more cases in
1998 and 82% more cases in 2003. Figure 2 demon-
s t r a t e st h e s ec h a n g e si nc o u n t sa sa g e - s e xs t a n d a r d i s e d
rates to allow for population increase. Between 1998
and 2003, there was a small decline (3.5%) in age-sex
standardised rates of admission for non-fatal MI-
HMDC. In contrast, rates of Positive MI (with troponin)
increased by 17% while rates of Positive MI (without
troponin) declined by 18%. Rates of Any MI (with tro-
ponin) increased by 24% while rates of Any MI (without
troponin) declined by 1.5%.
Discussion
The introduction of troponins as highly sensitive and
specific diagnostic tests for MI has revolutionised the
clinical management of suspected myocardial infarction,
but while their utility in clinical practice is unquestioned,
problems in monitoring population trends in MI remain
unresolved. We have made a three-way comparison of
counts of MI-HMDC, MI-AHA (with troponin) and MI-
AHAck (without troponin). When troponin is included in
the AHA classification, MI-HMDC overestimated counts
of Positive MI in 1998 but under-estimated the counts in
2003. This disparity between the clinical (coded) diagno-
sis in 2003 is in agreement with the finding by Roger and
colleagues in their prospective study of the effects of tro-
ponin tests on counts of MI in Olmsted County, that
found substantially lower counts of cases with a final
coded diagnosis of MI in medical records compared with
counts based on troponin tests [10]. They attributed this
to a reluctance by clinicians to always accept relatively
low levels of troponin as diagnostic of MI.
In contrast, when troponin was excluded from the
AHA classification, MI-HMDC overestimated counts of
Figure 1 Box plots of distribution of maximum values for troponin I and T according to HMDC coding of MI or not MI in cases
classified as AHA Definite or Probable MI (Positive MI) based on positive troponin tests but non-specific or normal ECGs in the 2003
validation sample. + indicates mean value of distribution; ￿ indicates extreme values beyond the y-axis scale. MI-HMDC represents true-positives
and HMDC Not MI represents false-negatives. HMDC: Hospital Morbidity Data Collection; MI: myocardial infarction.
a p < 0.0001 and
b p = 0.0006
for MI vs not MI (two-sided Wilcoxon rank sum test with normal approximation).
Sanfilippo et al. BMC Cardiovascular Disorders 2011, 11:35
http://www.biomedcentral.com/1471-2261/11/35
Page 5 of 8Positive MI which actually decreased between 1998 and
2003. There was an even greater difference between the
increasing rates of MI-AHA (with troponin) and the
decreasing rates of MI-AHAck (without troponin). The
decrease in MI-AHAck is consistent with the decline in
admission rates for MI in Perth in the 10 years prior to
the introduction of troponin tests [11]. The marked
divergence between MI-AHA (with troponin) and MI-
AHAck is also consistent with a further study in
Olmsted County that found that from 1987 to 2006,
rates of MI declined by 20% when traditional biomar-
kers only were used in the diagnosis of MI, whereas
rates of MI increased when based on troponin tests [14].
An essential requirement for monitoring MI is that
classification should be based on objective criteria that
remain constant over time. In the case of troponin-
based criteria this is unlikely because of progressive low-
ering of diagnostic thresholds as the precision of tests
improves, and because of variation within and between
hospitals in the several commercial, non-standardised
tests in use. This is likely to increase the number of
false negative cases. A further likely reason for the
increase in false-negative cases in 2003 was the marked
general increase (from 33 to 66%) in use of troponin
tests in all cardiac admissions other than MI or UAP.
Thus, even though the prevalence of positive troponin
tests in such cases was small, it had a relatively large
negative impact on the sensitivity of MI-HMDC against
MI-AHA.
Strengths of the study
Western Australia is geographically isolated with rela-
tively small population losses from emigration, and is
thus ideal for epidemiological studies. It has comprehen-
sive, linked health statistics systems spanning 30 years
[13], and has been the site of several previous studies of
trends in MI, including the WHO MONICA Project
[9,13,15]. Record linkage allowed us to define 28-day
episodes of care, thus eliminating inflation due to trans-
fers and early readmissions, and provided a total popula-
tion sampling frame for validation studies. Direct linkage
of HMDC records to laboratory records of biomarker
results allowed us to identify efficiently any potential
false-negative cases of MI. Finally, despite the rapid
uptake of troponin tests in Perth, the continued high
use of CK tests in the diagnosis of MI allowed us to
classify cases using both new and traditional biomarkers,
Table 4 Hierarchical diagnosis and classification of myocardial infarction based on AHA Criteria using only CK
biomarkers
Year HMDC episodes of care AHA classification of MI
a n (row%, col%)
Hierarchical diagnosis Count Positive MI Any MI Not MI
1998 MI 1420 816 (57.5, 89.4) 999 (70.4, 88.5) 421 (29.6, 17.6)
Unstable angina 2011 89 (4.4, 9.8) 115 (5.7, 10.2) 1896 (94.3, 79.2)
Other IHD
b 22 4 (18.2, 0.4) 4 (18.2, 0.3) 18 (81.8, 0.8)
Other CVD
b 69 4 (5.8, 0.4) 11 (15.9, 1.0) 58 (84.1, 2.4)
Total 3522 913 1129 2393
2003 MI 1579 752 (47.6, 88.2) 962 (60.9, 87.1) 617 (39.1, 28.1)
Unstable angina 1493 67 (4.5, 7.8) 99 (6.6, 9.0) 1394 (93.4, 63.6)
Other IHD
b 48 11 (22.9, 1.3) 13 (27.1, 1.2) 35 (72.9, 1.6)
Other CVD
b 177 23 (13.0, 2.7) 30 (17.0, 2.7) 147 (83.0, 6.7)
Total 3297 853 1104 2193
For non-fatal population estimates in 1998 and 2003 using only CK or CK-MB biomarker results. AHA: American Heart Association; CK: creatinine kinase; CK-MB:
MB isoenzyme of CK; CVD: cardiovascular disease; HMDC: Hospital Morbidity Data Collection; MI: myocardial infarction; MI-HMDC: MI coded in the HMDC; Positive
MI: AHA Definite or Probable MI; Any MI: AHA Definite/Probable/Possible MI; IHD: ischaemic heart disease.
a Luepker et al [12]. Row% represents positive predictive value, col% represents sensitivity.
b As listed in Table 1 (Other CVD includes chest pain).
Figure 2 Trends in age-sex standardized admission rates for
non-fatal MI in age group 35-79 years as recorded in the
HMDC compared with AHA classification of MI. AHA: American
Heart Association; HMDC: Hospital Morbidity Data Collection; MI:
myocardial infarction; Any MI: AHA Definite/Probable/Possible MI;
Positive MI: AHA Definite or Probable MI; MI-HMDC: MI coded in the
HMDC.
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tests on the diagnosis of MI in administrative data over
time.
Limitations
Limited resources forced us to adopt a sampling strategy
to validate the coding of MI in the HMDC. If sampling
was not strictly random, errors may have occurred in
population estimates. Our strategy of linking biomarker
test results to identify possible false-negative cases of MI
in the HMDC may have identified some cases in which
elevated troponins were not due to an acute ischaemic
event (for example, in chronic heart failure) but which
nevertheless met the ‘AHA criteria’ for MI. Lack of sta-
tistical power due to limited resources also prevented us
from fully exploring possible differences in the impact
of troponins on rates of MI by age and gender.
Conclusions
Our study has identified a number of issues for further
investigation before the predominately troponin-based
‘AHA criteria’ can be used with confidence in studies
of trends in MI. The most urgent need is for calibra-
tion of the several commercial troponin tests in use,
and for agreement on stratification of troponin results
that would permit valid comparison of positive tests
over time, despite changing diagnostic thresholds.
While universal standardization of troponin tests is
unlikely ever to be possible, calibration for studies of
trends at regional level, particularly when only a few
laboratories are involved, should be possible. This
would not invalidate comparative studies within or
between countries in which the primary focus is on
trends rather than cross-sectional differences between
rates, and providing that the methods of calibration
are explicitly described.
In view of the marked general increases in the use of
troponin tests in acutely ill patients with both cardiac
and non-cardiac conditions, further research is required
to determine whether the search for false-negative cases
should be restricted to cases coded within the ICD rub-
rics for ischaemic heart disease or chest pain.
Finally, the International expert panel made no
recommendations about the AHA categories of MI
(Definite, Probable, Possible) that should be included
in epidemiological studies. Definite plus Probable MI
in the AHA classification appears to be comparable to
“Definite MI” used as the main non-fatal event in the
MONICA Project [16] and appears to be similar to the
definition of MI used in the Atherosclerosis Risk in
Communities (ARIC) study [17]. Whether Possible MI
(or any subset thereof) should also be included needs
to be determined.
What is already known on this subject
￿ Troponin tests increase counts of myocardial infarc-
tion (MI) in administrative data compared with counts
based on traditional cardiac biomarkers.
￿ Long-term trends in MI based on traditional bio-
markers are declining, whereas those based on troponin
tests are increasing.
￿ Increased counts of MI associated with troponin
tests using revised criter i af o rM Ia r eo n l yp a r t l y
reflected in administrative data, possibly because physi-
cians are reluctant to diagnose MI on the basis of rela-
tively small increases in troponin levels.
What this study adds
￿ This is the first population-wide study to explore the
practical issues of implementing the revised criteria for
myocardial infarction (MI) for use in epidemiological
studies published by the American Heart Association
(AHA) International panel in 2003. It shows that for
trend analysis at least, the AHA criteria are flawed
b e c a u s et h e yd on o tr e c o g n i s ev a r i a t i o ni nt r o p o n i n
assay thresholds in different laboratories or changes in
diagnostic thresholds over time. This problem will
increase with the development of even more sensitive
troponin assays.
￿ Studies of trends in MI (as exemplified by the WHO
MONICA Project) have a basic requirement for unchan-
ging objective criteria. Our study identifies further work
that is required to standardise troponin testing for ana-
lysis of trends, particularly at the International level, if
the AHA criteria are to have any utility.
￿ Future epidemiological studies using AHA criteria
will need to recognise the large increase in false-negative
cases of MI associated with the large general increase in
t h ep r e v a l e n c eo ft r o p o n i nt esting in cases with other
cardiac conditions or chest pain.
￿ Since the introductions of troponins, routinely col-
lected hospital statistics no longer reflect true underly-
ing trends in MI.
Additional material
Additional file 1: Methods: Additional Detail. Provides additional
information on the selection of the validation sample, and the
classification of biomarkers, ECGs and symptoms using AHA definitions.
Includes two additional tables associated with methods and results
sections of the main text, including Table 1 from the AHA 2003
classification [12] showing counts from our validation samples.
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